Pulmonx (LUNG) EBT (2019 - 2025)

Pulmonx (LUNG) has reported EBT for 7 consecutive years, with -$13.8 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, EBT rose 0.88% year-over-year to -$13.8 million in Q3 2025; TTM through Sep 2025 was -$56.3 million, a 0.22% change from a year earlier, with the FY2024 full-year figure at -$55.9 million, up 7.26% from the prior year.
• EBT was -$13.8 million for Q3 2025 at Pulmonx, up from -$15.0 million in the prior quarter.
• Over five years, EBT peaked at -$10.1 million in Q3 2021 and troughed at -$16.1 million in Q2 2023.
• A 5-year average of -$14.0 million and a median of -$14.0 million in 2022 frame the typical range for EBT.
• Across the five-year window, EBT sank 165.99% in 2021 and increased 13.81% in 2024, its largest moves.
• Over 5 years, EBT stood at -$12.9 million in 2021, then slipped by 9.2% to -$14.0 million in 2022, then advanced by 2.83% to -$13.6 million in 2023, then climbed by 3.69% to -$13.1 million in 2024, then retreated by 5.27% to -$13.8 million in 2025.
• The last three EBT figures came in at -$13.8 million (Q3 2025), -$15.0 million (Q2 2025), and -$14.3 million (Q1 2025), per Business Quant data.